Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring

NCT07930182 is a recruiting, non-randomized phase 2 Moffitt trial (estimated enrollment 56) of neoadjuvant or adjuvant nivolumab, with ipilimumab added for ctDNA-defined escalation, using serial tumor-informed Haystack MRD plasma testing in resectable or resected cutaneous melanoma; primary endpoints are event-free survival in the neoadjuvant cohort and relapse-free survival in the adjuvant cohort.

H. Lee Moffitt Cancer Center and Research Institute